Loading...
Market
Blenrep's global market share in multiple myeloma treatments by December 31, 2025
2
American Society of Hematology•San Diego•California•Belantamab Mafodotin•China•National Medical Products Administration•NMPA•Blenrep
Resolution / Starting Odds
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Market analysis reports from firms like IQVIA or Frost & Sullivan
Story
GSK's Blenrep Reduces Death Risk by 42% in Blood Cancer Trial, Gains Priority Review in China
Dec 9, 2024, 06:36 PM
GSK has presented positive results from a Phase III clinical trial at the 2024 American Society of Hematology (ASH) Annual Meeting in San Diego, California. The trial evaluated the company's blood cancer treatment, Belantamab Mafodotin (Blenrep), showing a significant reduction in the risk of death by 42% for patients with relapsed or refractory multiple myeloma. This outcome suggests a potential revival for the drug, which was withdrawn from the market two years ago. Additionally, China’s National Medical Products Administration (NMPA) has accepted GSK's application for a combination therapy involving Blenrep, granting it priority review status for relapsed/refractory multiple myeloma, supported by the DREAMM-7 trial results.
View original story
Similar markets
Less than 10% • 25%
10%-20% • 25%
20%-30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 19% • 25%
20% to 29% • 25%
30% or more • 25%
Less than $500 million • 25%
$500 million - $1 billion • 25%
$1 billion - $1.5 billion • 25%
More than $1.5 billion • 25%
Increase by more than 20% • 25%
Increase between 10% and 20% • 25%
Increase by less than 10% • 25%
No significant increase • 25%
BridgeBio Pharma • 25%
Pfizer • 25%
Other • 25%
Tie • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 20% • 25%
20% to 40% • 25%
41% to 60% • 25%
More than 60% • 25%
Below 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
Above 60% • 25%
Less than 20% • 25%
20%-40% • 25%
40%-60% • 25%
More than 60% • 25%
Less than 5% • 25%
5% - 10% • 25%
10% - 15% • 25%
More than 15% • 25%